Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

Also called NCT01474538

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01474538
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01474538. Randomized; triple masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-03-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin Lispro
Intervention (Drug)
Insulin Aspart
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01474538
Content hash
7548dbe621005e35a38b5e03f9a989e71daefed1c0b7d4f68cdeeb0a91aa6ad4